<!DOCTYPE html>
<html lang="en-US">
<meta charset="UTF-8">

<title>OB/GYN Referenced</title>
<meta name="theme-color" content="#000000" />
<meta name="description" content="Abnormal Uterine Bleeding/Adolescents/Cancer Treatment">
<meta name="viewport" content="width=device-width, initial-scale=1">
<link rel="shortcut icon" href="favicon.ico" type="image/x-icon">
<link rel="manifest" href="manifest.json">
<link rel="stylesheet" href="css/w3.css">
<link rel="stylesheet" href="css/hg.css">


<body onload="SetUpPage()">

    <header id="MyHeader" class="hg-NavBar">
        <a id="bkbtn" class="hg-BackButton" href="javascript:void(0)" onclick="goBack()"></a>
        <a id="hmbrgbtn" class="hg-HamBtn" href="javascript:void(0)" onclick="SideBarOpen()"></a>
        <span id="titbar" class="hg-NavBarTitle"></span>
    </header>

    <nav class="hg-SideBar" id="mySidebar"></nav>

    <div class="hg-OverLay  " onclick="SideBarClose()" title="close side menu" id="myOverlay"></div>

    <div class="hg-Content">

        <main class="hg-InfoContent">
            <h1 class="hg-h1PageTitle">Abnormal Uterine Bleeding/Adolescents/Cancer Treatment</h1>

            <h2 class="hg-h2SectionTitle">General</h2>
            <section class="accordian">
                <button onclick="AccToggle('aubalcainco')" class="hg-accBtn">Initial considerations:<span
                        id="aubalcainco_c" class="hg-NavLinkChevron"></span></button>
                <div id="aubalcainco" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Risk thromboembolism (eg combined oral contraceptive contraindicated with bone marrow or
                            stem cell transplant).<sup>1</sup></li>
                        <li>Need for contraception.<sup>1</sup></li>
                        <li>Emetogenic potential.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <h2 class="hg-h2SectionTitle">Acute Management</h2>
            <section class="accordian">
                <button onclick="AccToggle('aubaldoacprqw')" class="hg-accBtn">Acute progestin therapy:<span
                        id="aubaldoacprqw_c" class="hg-NavLinkChevron"></span></button>
                <div id="aubaldoacprqw" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Medroxyprogesterone acetate 60-80 mg orally BID until bleeding controlled and then progestin
                            taper.<sup>1</sup></li>
                        <li class="hg-accOr" />
                        <li>Norethindrone acetate (Aygestin) 10-20 mg orally every 8 hours until bleeding controlled and
                            then progestin taper.<sup>1</sup></li>
                    </ul>
                    <P class="hg-accNoteBlank"><span style="font-weight: bold;">Progestin taper:</span>
                        Medroxyprogesterone acetate 10 mg orally every 4-6 hours as needed to
                        manage bleeding.<sup>1</sup></P>
                </div>
            </section>
            <section class="accordian">
                <button onclick="AccToggle('aubacestrwf')" class="hg-accBtn">Acute estrogen therapy:<span
                        id="aubacestrwf_c" class="hg-NavLinkChevron"></span></button>
                <div id="aubacestrwf" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Continuous combined oral contraceptive taper. Monophasic 30-50 mcg ethinyl
                            estradiol/norgestrel or levonorgestrel every 6-8 hours and taper as needed to manage
                            bleeding. Skip placebos and take continuously.<sup>1</sup></li>
                        <li class="hg-accOr" />
                        <li>Premarin 25 mg IV every 4 hours to decrease bleeding then continuous combined oral
                            contraceptive taper as above. Consider antiemetics.<sup>1</sup></li>
                    </ul>
                </div>
            </section>
            <section class="accordian">
                <button onclick="AccToggle('aubactmensupab')" class="hg-accBtn">Menstrual suppression:<span
                        id="aubactmensupab_c" class="hg-NavLinkChevron"></span></button>
                <div id="aubactmensupab" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Leuprolide acetate with norethindrone acetate 5 mg daily add-back as below.<sup>1</sup></li>
                        <li class="hg-accOr" />
                        <li>Progestin-only therapy as below.<sup>1</sup></li>
                        <li class="hg-accOr" />
                        <li>Continuous combined oral contraceptive as below.<sup>1</sup></li>
                    </ul>
                </div>
            </section>
            <section class="accordian">
                <button onclick="AccToggle('aubrefracref')" class="hg-accBtn">Refractory bleeding<span
                        id="aubrefracref_c" class="hg-NavLinkChevron"></span></button>
                <div id="aubrefracref" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Alternate acute management (Progestin | Estrogen).<sup>1</sup></li>
                        <li>Possible pelvic ultrasound for endometrial thickness to guide treatment.<sup>1</sup></li>
                        <li>Possible antifibrinolytics (oral or IV tranexamic acid).<sup>1</sup></li>
                        <li>Possible intrauterine foley.<sup>1</sup></li>
                        <li>Possible suction curettage with Levonorgestrel-releasing IUD.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <h2 class="hg-h2SectionTitle">Menstrual Suppression</h2>
            <section class="accordian">
                <button onclick="AccToggle('aubmsov')" class="hg-accBtn">Overview:<span id="aubmsov_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="aubmsov" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Use prophylactically or after acute management.<sup>1</sup></li>
                    </ul>
                </div>
            </section>
            <section class="accordian">
                <button onclick="AccToggle('aubmsleac')" class="hg-accBtn">Leuprolide acetate (GnRH agonist):<span
                        id="aubmsleac_c" class="hg-NavLinkChevron"></span></button>
                <div id="aubmsleac" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Advantages:<sup>1</sup>
                            <ul>
                                <li>Best used for menstrual suppression. High rates of amenorrhea (up to
                                    96%).<sup>1</sup></li>
                                <li>Not prothrombotic.<sup>1</sup></li>
                                <li>Possible chemotherapy protective effect on premature ovarian failure but no evidence
                                    preserves fertility.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li>Disadvantages:<sup>1</sup>
                            <ul>
                                <li>Not contraception.<sup>1</sup></li>
                                <li>Initial flare with AUB 1st 2-3 weeks. Norethindrone acetate 5 mg daily may decrease.
                                    If severe can use acute management options.<sup>1</sup></li>
                                <li>Low estrogen effects of vasomotor symptoms and bone loss. Decreased with concurrent
                                    use of add-back therapy.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li>Regimens:<sup>1</sup>
                            <ul>
                                <li>3.75 mg IM monthly / 11.5 mg IM every 12 weeks / Subcutaneous form available if IM
                                    hematoma concerns.<sup>1</sup></li>
                                <li>Add-back: Norethindrone acetate 5 mg daily reasonable to start with onset of
                                    therapy.<sup>1</sup></li>
                                <li>Add-back: Norethindrone acetate 5 mg + conjugated equine estrogen 0.625 mg daily has
                                    more benefits on bone density if not contraindicated.<sup>1</sup></li>
                            </ul>
                        </li>
                    </ul>

                </div>
            </section>
            <section class="accordian">
                <button onclick="AccToggle('auborileswc')" class="hg-accBtn">Elagolix (Orilissa) (oral GnRH
                    antagonist):<span id="auborileswc_c" class="hg-NavLinkChevron"></span></button>
                <div id="auborileswc" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Oral therapy and amenorrhea rate like leuprolide acetate but no current guidance for use
                            with cancer treatment.<sup>1</sup></li>
                    </ul>
                </div>
            </section>
            <section class="accordian">
                <button onclick="AccToggle('aubprogontx')" class="hg-accBtn">Progestin-only therapy:<span
                        id="aubprogontx_c" class="hg-NavLinkChevron"></span></button>
                <div id="aubprogontx" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Medroxyprogesterone acetate:<sup>1</sup>
                            <ul>
                                <li>10–20 mg orally/day.<sup>1</sup></li>
                                <li>Not contraception.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li class="hg-accOr" />
                        <li>Norethindrone acetate (Aygestin):<sup>1</sup>
                            <ul>
                                <li>5-15 mg orally/day.<sup>1</sup></li>
                                <li>Not contraception.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li class="hg-accOr" />
                        <li>Drospirenone (Slynd):<sup>1</sup>
                            <ul>
                                <li>4 mg orally/day.<sup>1</sup></li>
                                <li>Contraception but more unscheduled bleeding.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li class="hg-accOr" />
                        <li>Norethindrone (Micronor, etc.):<sup>1</sup>
                            <ul>
                                <li>0.35 mg orally/day.<sup>1</sup></li>
                                <li>Contraception but more unscheduled bleeding.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li class="hg-accOr" />
                        <li>Depot Medroxyprogesterone Acetate IM:<sup>1</sup>
                            <ul>
                                <li>50-70% amenorrheic in 12-24 months but initially high break through bleeding
                                    rate.<sup>1</sup></li>
                                <li>Subcutaneous form available if IM hematoma concerns.<sup>1</sup></li>
                            </ul>
                        </li>
                        <li class="hg-accOr" />
                        <li>LARC:<sup>1</sup>
                            <ul>
                                <li>Levonorgestrel-releasing IUD:<sup>1</sup>
                                    <ul>
                                        <li>32% amenorrheic 3 months.<sup>1</sup></li>
                                        <li>Can be used in immunosuppressed.<sup>1</sup></li>
                                        <li>If pre-existing and bleeding can use progestin taper.<sup>1</sup></li>
                                    </ul>
                                </li>
                                <li>Etonogestrel single-rod implant:<sup>1</sup>
                                    <ul>
                                        <li>Irregular bleeding limits use for menstrual suppression.<sup>1</sup></li>
                                        <li>If pre-existing and bleeding can use progestin taper.<sup>1</sup></li>
                                    </ul>
                                </li>
                            </ul>
                            
                        </li>
                    </ul>
                    <P class="hg-accNoteBlank"><span style="font-weight: bold;">Progestin taper:</span>
                        Medroxyprogesterone acetate 10 mg orally every 4-6 hours as needed to
                        manage bleeding.<sup>1</sup></P>
                </div>
            </section>
            <section class="accordian">
                <button onclick="AccToggle('aubccccaal')" class="hg-accBtn">Continuous combined oral contraceptive:<span id="aubccccaal_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="aubccccaal" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Emetogenic.<sup>1</sup></li>
                        <li>Risk VTE (eg Bone marrow and stem cell transplants have increased risk hyperbilirubinemia and hepatic veno-occlusive disease).<sup>1</sup></li>
                    </ul>
                </div>
            </section>
	
            
                       <!--   <section class="accordian hg-accSectionRelTopics">
                <button onclick="AccToggle('xxxRelLinks')" class="hg-accBtn">Related topics:<span id="xxxRelLinks_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="xxxRelLinks" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li><a href="xxx.html">XXX</a></li>
                    </ul>
                </div>
            </section> -->


            <section class="accordian hg-accSectionRef">
                <button onclick="AccToggle('aubrefaldouRefs')" class="hg-accBtn">References:<span id="aubrefaldouRefs_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="aubrefaldouRefs" class="hg-accDivMain">
                    <ol class="hg-accOlRef">
                        <li>Options for prevention and management of menstrual bleeding in adolescent patients
                            undergoing cancer treatment. ACOG Committee Opinion No. 817. American College of
                            Obstetricians and Gynecologists. Obstet Gynecol 2021;137:e7–15.</li>
                    </ol>
                </div>
            </section>

        </main>

            <div class="hg-AddContent">
                <p class="hg-AddSmall ">AD</p>
                <p class="hg-AddLarge  ">AD</p>
            </div>

    </div>

    <script defer src="script.js"></script>
    <script defer src="script-aux.js"></script>

</body>

</html>